Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Zura Bio Ltd

Get SEC filing alerts via email and in your feed for Zura Bio Ltd

ZURA ZURAW

Zura Bio Ltd

About Zura Bio Ltd

Zura Bio Limited is a clinical-stage biopharmaceutical company focused on developing innovative dual-pathway antibodies for autoimmune and inflammatory diseases. Its pipeline includes candidates targeting cytokines like IL-17, BAFF, IL-7, and IL-33, with potential to address unmet medical needs. The company leverages licensed technologies, collaborates with major pharma partners, and advances therapies through clinical trials aimed at broad immune modulation.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Zura Bio Ltd

1
1
Zura Bio Ltd Zura Bio Limited Reports $24.2 Million Net Loss in Q1 2026, Increases Liquidity to $225.6 Million

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Zura Bio Ltd Zura Bio Ltd. Reports $68.7 Million Net Loss for 2025, Highlights Clinical Trials and Financial Developments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Zura Bio Ltd Zura Bio Reports $18M Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Zura Bio Ltd Zura Bio Limited Reports Increased Net Losses and Rising Operating Expenses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Zura Bio Ltd Zura Bio Limited Reports $17.4 Million Net Loss and Increased R&D Expenses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Zura Bio Ltd Zura Bio Reports $45.4 Million Net Loss for Fiscal Year 2024, Improved from $69.2 Million in 2023

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Zura Bio Ltd Zura Bio Reports Significant Financial Developments, Including 90% Increase in Operating Expenses and $188.2 Million in Cash and Cash Equivalents

Via official filing (AI summary) | over 1 year ago | 0 comments